Canaccord Genuity weighs in on Columbia Laboratories (CBRX +2.2%) after the firm was rocked by a...

|By:, SA News Editor

Canaccord Genuity weighs in on Columbia Laboratories (CBRX +2.2%) after the firm was rocked by a FDA rejection of its preterm birth prevention gel. Though analyst Randall Stanicky acknowledges the "disappointment," he still sees potential for CBRX and rival Watson Pharmaceuticals (WPI -3.4%) on possible M&A activity and the under-leveraged balance sheets the firms carry.